Hypoxia-inducible factor (HIF) in human tumorigenesis

Histology and Histopathology

Volumn 22, Issue 4-6, 2007, Pages 559-572

  Mabjeesh, Nicola J ^a   Amir, S ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Hypoxia inducible factor (HIF); Immunohistochemistry; Patients; Prognosis; Tumor

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HIF1A PROTEIN, HUMAN; OXYGEN; UNCLASSIFIED DRUG;

ANGIOGENESIS; BLADDER CARCINOGENESIS; BRAIN TUMOR; BREAST CARCINOGENESIS; CANCER SURVIVAL; CARCINOGENESIS; COLORECTAL CANCER; ESOPHAGUS CANCER; HEAD AND NECK CANCER; HUMAN; HYPOXIA; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG CARCINOGENESIS; NASOPHARYNX CARCINOMA; OVARY CANCER; PANCREAS CANCER; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REVIEW; SOLID TUMOR; STOMACH CANCER; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION; CELL HYPOXIA; FEMALE; GENETIC TRANSCRIPTION; GENETICS; MALE; METABOLISM; NEOPLASM; PATHOLOGY; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

CELL HYPOXIA; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASMS; OXYGEN; PROGNOSIS; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 34247537548     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (134)

1. Anastasiadis A.G., Ghafar M.A., Salomon L., Vacherot F., Benedit P., Chen M.W., Shabsigh A., Burchardt M., Chopin D.K., Shabsigh R. and Buttyan R. (2002). Human hormone-refractory prostate cancers can harbor mutations in the O(2)-dependent degradation domain of hypoxia inducible factor-1alpha (HIF-1alpha). J. Cancer Res. Clin. Oncol. 128, 358-362.
2. Beasley N.J., Leek R., Alam M., Turley H., Cox G.J., Gatter K., Millard P., Fuggle S. and Harris A.L. (2002). Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res. 62, 2493-2497.
3. Birner P., Schindl M., Obermair A., Breitenecker G. and Oberhuber G. (2001). Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin. Cancer Res. 7, 1661-1668.
4. Blouw B., Song H., Tihan T., Bosze J., Ferrara N., Gerber H.P., Johnson R.S. and Bergers G. (2003). The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 4, 133-146.
5. Boddy J.L., Fox S.B., Han C., Campo L., Turley H., Kanga S., Malone P.R. and Harris A.L. (2005). The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer. Clin. Cancer Res. 11, 7658-7663.
6. Bos R., Zhong H., Hanrahan C.F., Mommers E.C., Semenza G.L., Pinedo H.M., Abeloff M.D., Simons J.W., van Diest P.J. and van der Wall E. (2001). Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J. Natl. Cancer Inst. 93, 309-314.
7. Bos R., van der Groep P., Greijer A.E., Shvarts A., Meijer S., Pinedo H.M., Semenza G.L., van Diest P.J. and van der Wall E. (2003). Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 97, 1573-1581.
8. Bos R., van Diest P.J., de Jong J.S., van der Groep P., van der Valk P. and van der Wall E. (2005). Hypoxia-inducible factor-1alpha is associated with angiogenesis, and expression of bFGF, PDGF-BB, and EGFR in invasive breast cancer. Histopathology 46, 31-36.
9. Brahimi-Horn M.C. and Pouyssegur J. (2005). The hypoxia-inducible factor and tumor progression along the angiogenic pathway. Int. Rev. Cytol. 242, 157-213.
10. Bruick R.K. and McKnight S.L. (2001). A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294, 1337-1340.
11. Carmeliet P., Dor Y., Herbert J.M., Fukumura D., Brusselmans K., Dewerchin M., Neeman M., Bono F., Abramovitch R., Maxwell P., Koch C.J., Ratcliffe P., Moons L., Jain R.K., Collen D., Keshert E. and Keshet E. (1998). Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394, 485-490.
12. Chau C.H., Permenter M.G., Steinberg S.M., Retter A.S., Dahut W.L., Price D.K. and Figg W.D. (2005). Polymorphism in the hypoxia-inducible factor 1alpha gene may confer susceptibility to androgen-Independent prostate cancer. Cancer Biol. Ther. 4.
13. Chen W.T., Huang C.J., Wu M.T., Yang S.F., Su Y.C. and Chai C.Y. (2005). Hypoxia-inducible factor-1alpha is associated with risk of aggressive behavior and tumor angiogenesis in gastrointestinal stromal tumor. Jpn. J. Clin. Oncol. 35, 207-213.
14. Couvelard A., O'Toole D., Turley H., Leek R., Sauvanet A., Degott C., Ruszniewski P., Belghiti J., Harris A.L., Gatter K. and Pezzella F. (2005a). Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br. J. Cancer 92, 94-101.
15. Couvelard A., O'Toole D., Leek R., Turley H., Sauvanet A., Degott C., Ruszniewski P., Belghiti J., Harris A.L, Gatter K. and Pezzella F. (2005b). Expression of hypoxia-inducible factors is correlated with the presence of a fibrotic focus and angiogenesis in pancreatic ductal adenocarcinomas. Histopathology 46, 668-676.
16. Dales J.P., Garcia S., Meunier-Carpentier S., Andrac-Meyer L., Haddad O., Lavaut M.N., Allasia C., Bonnier P. and Charpin C. (2005). Overexpression of hypoxia-inducible factor HIF-1alpha predicts early relapse in breast cancer: retrospective study in a series of 745 patients. Int. J. Cancer 116, 734-739.
17. Dang D.T., Chen F., Gardner L.B., Cummins J.M., Rago C., Bunz F., Kantsevoy S.V. and Dang L.H. (2006). Hypoxia-inducible factor-1alpha promotes nonhypoxia-mediated proliferation in colori cancer cells and xenografts. Cancer Res. 66, 1684-1936.
18. Deng J.H., Bai J.L., Ma P.C., Zhang S.S. and Wan J.H. (2006). [Expression and significance of GST-Pi and HIF-1alpha in bladder carcinoma]. Ai Zheng 25, 190-193.
19. Ding L., Chen X.P. and Wang H.P. (2004). [Expression and clinical significance of HIF-1a protein in hepatocellular carcinoma tissues.]. Zhonghua Gan Zang Bing Za Zhi 12, 656-659.
20. Du Z., Fujiyama C., Chen Y. and Masaki Z. (2003). Expression of hypoxia-inducible factor 1alpha in human normal, benign, and malignant prostate tissue. Chin. Med. J. (Engl) 116, 1936-1939.
21. Epstein A.C., Gleadle J.M., McNeill L.A., Hewitson K.S., O'Rourke J., Mole D.R., Mukherji M., Metzen E., Wilson M.I., Dhanda A., Tian Y.M., Masson N., Hamilton D.L., Jaakkola P., Barstead R., Hodgkin J., Maxwell P.H., Pugh C.W., Schofield C.J. and Ratcliffe P.J. (2001). C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107, 43-54.
22. Fan L.F., Diao L.M., Chen D.J., Liu M.Q., Zhu L.Q., Li H.G., Tang Z.J., Xia D., Liu X. and Chen H.L. (2002). Expression of HIF-1 alpha and its relationship to apoptosis and proliferation in lung cancer. Ai Zheng 21, 254-258.
23. Fan L.F., Diao L.M., Jiang C.Q., Tang Z.J., Xia D., Liu M.Q., Liu Z.S. and Ai Z.L. (2004). Expression and pathobiological implication of hypoxia-inducible factor-1alpha in human colorectal carcinoma. Zhonghua Bing Li Xue Za Zhi 33, 242-246.
24. Fillies T., Werkmeister R., van Diest P.J., Brandt B., Joos U. and Buerger H. (2005). HlFl-alpha overexpression indicates a good prognosis in early stage squamous cell carcinomas of the oral floor. BMC Cancer 5, 84.
25. Fu X.S., Choi E., Bubley G.J. and Balk S.P. (2005). Identification of hypoxia-inducible factor-1alpha (HIF-1alpha) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation. Prostate 63, 215-221.
26. Giannopoulou E., Ravazoula P., Kalofonos H., Makatsoris T. and Kardamakis D. (2006). Expression of HIF-1alpha and iNOS in astrocytic gliomas: a clinicopathological study. In Vivo 20, 421-425.
27. Giatromanolaki A., Koukourakis M.I., Sivridis E., Turley H., Talks K., Pezzella F., Gatter K.C. and Harris A.L. (2001). Relation of hypoxia inducible factor I alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br. J. Cancer 85, 881-890.
28. Gong K., Zhang N., Na X., Wu G., Yang X.Y., Xin D.Q. and Na Y.Q. (2005). The expression of hypoxia inducible factor-l,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene. Zhonghua Wai Ke Za Zhi 43, 390-393.
29. Griffiths E.A., Pritchard S.A., Welch I.M., Price P.M. and West C.M. (2005). Is the hypoxia-inducible factor pathway important in gastric cancer? Eur. J. Cancer 41, 2792-2805.
30. Gruber G., Greiner R.H., Hlushchuk R., Aebersold D.M., Altermatt H.J., Berclaz G. and Djonov V. (2004). Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter? Breast Cancer Res. 6, R191-198.
31. Gu Y.Z., Moran S.M., Hogenesch J.B., Wartman L. and Bradfield C.A. (1998). Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha. Gene Expr. 7, 205-213.
32. Guo H.F., Gong K., Zou S.M., Zhang Z.W., Liu X.Y., Na X., Wu G. and Na Y.Q. (2004). Somatic mutations of VHL gene and HIF-1alpha expression in primary renal clear cell carcinomas. Zhonghua Wai Ke Za Zhi 42, 196-200.
33. Hao P., Chen X., Geng H., Gu L., Chen J. and Lu G. (2004). Expression and implication of hypoxia inducible factor-1alpha in prostate neoplasm. J. Huazhong Univ. Sci. Technolog. Med. Sci. 24, 593-595.
34. Helton R., Cui J., Scheel J.R., Ellison J.A., Ames C., Gibson C., Blouw B., Ouyang L., Dragatsis I., Zeitlin S., Johnson R.S., Lipton S.A. and Barlow C. (2005). Brain-specific knock-out of hypoxia-inducible factor-1alpha reduces rather than increases hypoxic-ischemic damage. J. Neurosci. 25, 4099-4107.
35. Hewitson K.S., McNeill L.A., Riordan M.V., Tian Y.M., Bullock A.N., Welford R.W., Elkins J.M., Oldham N.J., Bhattacharya S., Gleadle J.M., Ratcliffe P.J., Pugh C.W. and Schofield C.J. (2002). Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J. Biol. Chem. 277, 26351-26355.
36. Hirota K. and Semenza G.L. (2006). Regulation of angiogenesis by hypoxia-inducible factor 1. Crit. Rev. Oncol. Hematol. 59, 15-26.
37. Hirota K., Fukuda R., Takabuchi S., Kizaka-Kondoh S., Adachi T., Fukuda K. and Semenza G.L. (2004). Induction of hypoxia-inducible factor 1 activity by muscarinic acetylcholine receptor signaling. J. Biol. Chem. 279, 41521-41528.
38. Hoskin P.J., Sibtain A., Daley F.M. and Wilson G.D. (2003). GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON. Br. J. Cancer 89, 1290-1297.
39. Huang G.W., Yang L.Y. and Lu W.Q. (2005). Expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in hepatocellular carcinoma: Impact on neovascularization and survival. World J. Gastroenterol. 11, 1705-1708.
40. Hui E.P., Chan A.T., Pezzella F., Turley H., To K.F., Poon T.C., Zee B., Mo F., Teo P.M., Huang D.P., Gatter K.C., Johnson P.J. and Harris A.L. (2002). Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin. Cancer Res. 8, 2595-2604.
41. Hur E., Chang K.Y., Lee E., Lee S.K. and Park H. (2001). Mitogen-activated protein kinase kinase inhibitor PD98059 blocks the transactivation but not the stabilization or DNA binding ability of hypoxia-inducible factor-1 alpha. Mol. Pharmacol. 59, 1216-1224.
42. Huss W.J., Hanrahan C.F., Barrios R.J., Simons J.W. and Greenberg N.M. (2001). Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res. 61, 2736-2743.
43. Irie N., Matsuo T. and Nagata I. (2004). Protocol of radiotherapy for glioblastoma according to the expression of HIF-1. Brain Tumor Pathol. 21, 1-6.
44. 2 sensing. Science 292, 464-468.
45. Jiang B.H., Jiang G., Zheng J.Z., Lu Z., Hunter T. and Vogt P.K. (2001). Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ. 12, 363-369.
46. Jiang C.Q., Liu Z.S., Qian Q., He Y.M., Yuan Y.F. and Ai Z.L. (2003a). Relationship of hypoxia-inducible factor 1 alpha (HIF-1alpha) gene expression with vascular endothelial growth factor (VEGF) and microvessel density (MVD) in human colorectal adenoma and adenocaminoma. Ai Zheng 22, 1170-1174.
47. Jiang Y.A., Fan L.F., Jiang C.Q., Zhang Y.Y., Luo H.S., Tang Z.J., Xia D. and Wang M. (2003b). Expression and significance of PTEN, hypoxia-inducible factor-1 alpha in colorectal adenoma and adenocarcinoma. World J. Gastroenterol. 9, 491-494.
48. Jiang C.Q., Fan L.F., Liu Z.S., Qian Q., Xia D., Diao L.M., He Y.M. and Ai Z.L. (2004). Expression levels and significance of hypoxia inducible factor-1 alpha and vascular endothelial growth factor in human colorectal adenocarcinoma. Chin. Meti. J. (Erigi) 117, 1541-1546.
49. Jones A., Fujiyama C., Blanche C., Moore J.W., Fuggle S., Cranston D., Bicknell R. and Harris A.L. (2001). Relation of vascular endothelial growth factor production to expression and regulation of hypoxia-inducible factor-1 alpha and hypoxia-inducible factor-2 alpha in human bladder tumors and cell lines. Clin. Cancer Res. 7, 1263-1272.
50. Kasuno K., Takabuchi S., Fukuda K., Kizaka-Kondoh S., Yodoi J., Adachi T., Semenza G.L. and Hirota K. (2004). Nitric oxide induces hypoxia-inducible factor 1 activation that is dependent on MAPK and phosphatidylinositol 3-kinase signaling. J. Biol. Chem. 279, 2550-2558.
51. Katsuta M., Miyashita M., Makino H., Nomura T., Shinji S., Yamashita K., Tajiri T., Kudo M., Ishiwata T. and Naito Z. (2005). Correlation of hypoxia inducible factor-1alpha with lymphatic metastasis via vascular endothelial growth factor-C in human esophageal cancer. Exp. Mol. Pathol. 78, 123-130.
52. Kaur B., Khwaja F.W., Severson E.A., Matheny S.L., Brat D.J. and Van Meir E.G. (2005). Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro-oncol. 7, 134-153.
53. Kim W. and Kaelin W.G. Jr. (2003). The von HippeI-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer. Curr. Opin. Genet. Dev. 13, 55-60.
54. Kim J.H., Jung C.W., Cho Y.H., Lee J., Lee S.H., Kim H.Y., Park J., Park J.O., Kim K., Kim W.S., Park Y.S., Im Y.H., Kang W.K. and Park K. (2005a). Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma. Oncol. Rep. 13, 859-864.
55. Kim S.J., Rabbani Z.N., Dewhirst M.W., Vujaskovic Z., Vollmer R.T., Schreiber E.G., Oosterwijk E. and Kelley M.J. (2005b). Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected nonsmall cell lung cancer. Lung Cancer 49, 325-335.
56. Kitada T., Seki S., Sakaguchi H., Sawada T., Hirakawa K. and Wakasa K. (2003). Clinicopathological significance of hypoxia-inducible factor-1alpha expression in human pancreatic carcinoma. Histopathology 43, 550-555.
57. Korkolopoulou P., Patsouris E., Konstantinidou A.E., Pavlopoulos P.M., Kavantzas N., Boviatsis E., Thymara I., Perdiki M., Thomas-Tsagli E., Angelidakis D., Rologis D. and Sakkas D. (2004). Hypoxia-inducible factor 1alpha/vascular endothelial growth factor axis in astrocytomas. Associations with microvessel morphometry, proliferation and prognosis. Neuropathol. Appl. Neurobiol. 30, 267-278.
58. Koukourakis M.I., Giatromanolaki A., Skarlatos J., Corri L., Blandamura S., Piazza M., Gatter K.C. and Harris A.L. (2001). Hypoxia inducible factor (HIF-1a and HIF-2a) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res. 61, 1830-1832.
59. Koukourakis M.I., Giatromanolaki A., Sivridis E., Simopoulos C., Turley H., Talks K., Gatter K.C. and Harris A.L. (2002). Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 53, 1192-1202.
60. Koukourakis M.I., Bentzen S.M., Giatromanolaki A., Wilson G.D., Daley F.M., Saunders M.I., Dische S., Sivridis E. and Harris A.L. (2006). Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J. Clin. Oncol. 24, 727-735.
61. Kronblad A., Jirstrom K., Ryden L., Nordenskjold B. and Landberg G. (2006). Hypoxia inducible factor-1alpha is a prognostic marker in premenopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response. Int. J. Cancer 118, 2609-2616.
62. Kurokawa T., Miyamoto M., Kato K., Cho Y., Kawarada Y., Hida Y., Shinohara T., Itoh T., Okushiba S., Kondo S. and Katoh H. (2003). Overexpression of hypoxia-inducible-factor 1alpha(HIF-1alpha) in oesophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Br. J. Cancer 89, 1042-1047.
63. Kuwai T., Kitadai Y., Tanaka S., Onogawa S., Matsutani N., Kaio E., Ito M. and Chayama K. (2003). Expression of hypoxia-inducible factor-1alpha is associated with tumor vascularization in human colorectal carcinoma. Int. J. Cancer 105, 176-181.
64. Kyzas P.A., Stefanou D., Batistatou A. and Agnantis N.J. (2005). Hypoxia-induced tumor angiogenic pathway in head and neck cancer: an in vivo study. Cancer Lett. 225, 297-304.
65. Lando E., Peet D.J., Gorman J.J., Whelan D.A., Whitelaw M.L. and Bruick R.K. (2002). FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 16, 1466-1471.
66. Laughner E., Taghavi P., Chiles K., Mahon P.C. and Semenza G.L. (2001). HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-I-mediated vascular endothelial growth factor expression. Mol. Cell Biol. 21, 3995-4004.
67. Lee C.H., Lee M.K., Kang C.D., Kim Y.D., Park do Y., Kim J.Y., Sol M.Y. and Suh K.S. (2003). Differential expression of hypoxia inducible factor-1 alpha and tumor cell proliferation between squamous cell carcinomas and adenocarcinomas among operable non-small cell lung carcinomas. J. Korean Med. Sci. 18, 196-203.
68. Li J., Shi M., Cao Y., Yuan W., Pang T., Li B., Sun Z., Chen L. and Zhao R.C. (2006). Knockdown of hypoxia-inducible factor-1alpha in breast carcinoma MCF-7 cells results in reduced tumor growth and increased sensitivity to methotrexate. Biochem. Biophys. Res. Commun. 342, 1341-1351.
69. Lidgren A., Hedberg Y., Grankvist K., Rasmuson T., Bergh A. and Ljungberg B. (2006). Hypoxia-Inducible Factor 1alpha Expression in Renal Cell Carcinoma Analyzed by Tissue Microarray. Eur. Urol.
70. Luo F., Liu X., Yan N., Li S., Cao G., Cheng Q., Xia Q. and Wang H. (2006). Hypoxia-inducible transcription factor-1alpha promotes hypoxia-induced A549 apoptosis via a mechanism that involves the glycolysis pathway. BMC Cancer 6, 26.
71. Mabjeesh N.J., Escuin D., LaVallee T.M., Pribluda V.S., Swartz G.M., Johnson M.S., Willard M.T., Zhong H., Simons J.W. and Giannakakou P. (2003). 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3, 363-375.
72. Mahon P.C., Hirota K. and Semenza G.L. (2001). FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-I transcriptional activity. Genes Dev. 15, 2675-2686.
73. Manalo D.J., Rowan A., Lavoie T., Natarajan L., Kelly B.D., Ye S.Q., Garcia J.G. and Semenza G.L. (2005). Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 105, 659-669.
74. Matsuyama T., Nakanishi K., Hayashi T., Yoshizumi Y., Aiko S., Sugiura Y., Tanimoto T., Uenoyama M., Ozeki Y. and Maehara T. (2005). Expression of hypoxia-inducible factor-1alpha in esophageal squamous cell carcinoma. Cancer Sci. 96, 176-182.
75. Maxwell P.H., Dachs G.U., Gleadle J.M., Nicholls L.G., Harris A.L., Stratford I.J., Hankinson O., Pugh C.W. and Ratcliffe P.J. (1997). Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl. Acad. Sci. USA 94, 8104-8109.
76. Metzen E., Berchner-Pfannschmidt U., Stengel P., Marxsen J.H., Stolze I., Klinger M., Huang W.Q., Wotzlaw C., Hellwig-Burgel T., Jelkmann W., Acker H. and Fandrey J. (2003). Intracellular localisation of human HIF-1 alpha hydroxylases: implications for oxygen sensing. J. Cell. Sci. 116, 1319-1326.
77. Minet E., Arnould T., Michel G., Roland I., Mottet D., Raes M., Remacle J. and Michiels C. (2000). ERK activation upon hypoxia: involvement in HIF-1 activation. FEBS Lett. 468, 53-58.
78. Minet E., Michel G., Mottet D., Raes M. and Michiels C. (2001). Transduction pathways involved in Hypoxia-Inducible Factor-1 phosphorylation and activation. Free Radic. Biol. Med. 31, 847-855.
79. Na X., Wu G., Ryan C.K., Schoen S.R., di'Santagnese P.A. and Messing E.M. (2003). Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. J. Urol. 170, 588-592.
80. Nakayama K., Kanzaki A., Hata K., Katabuchi H., Okamura H., Miyazaki K., Fukumoto M. and Takebayashi Y. (2002). Hypoxia-inducible factor I alpha (HIF-1 alpha) gene expression in human ovarian carcinoma. Cancer Lett. 176, 215-223.
81. Neckers L. (2003). Development of small moleoule Hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification. Curr. Med. Chem. 10, 733-739.
82. Neckers L. (2006). Using natural product inhibitors to validate hsp90 as a molecular target in cancer. Curr. Top. Med. Chem. 6, 1163-1171.
83. Okada K., Osaki M., Araki K., Ishiguro K., Ito H. and Ohgi S. (2005). Expression of hypoxia-inducible factor (HIF-1alpha), VEGF-C and VEGF-D in non-invasive and invasive breast ductal carcinomas. Anticancer Res. 25, 3003-3009.
84. Ollerenshaw M., Page T., Hammonds J. and Demaine A. (2004). Polymorphisms in the hypoxia inducible factor-1alpha gene (HIF1A) are associated with the renal cell carcinoma phenotype. Cancer Genet. Cytogenet. 153, 122-126.
85. Orr-Urtreger A., Bar-Shira A., Matzkin H. and Mabjeesh N. (2006). The homozygous P582S mutation in the Oxygen-dependent degradation domain of HIF-1-alfa is associated with increased risk to prostate cancer. Prostate (in press).
86. Page E.L., Robitaille G.A,, Pouyssegur J. and Richard D.E. (2002). Induction of hypoxia-inducible factor-1alpha by transcriptional and translational meohanisms. J. Biol. Chem. 277, 48403-48409.
87. Palit V., Phillips R.M., Puri R., Shah T. and Bibby M.C. (2005). Expression of HIF-1alpha and Glut-1 in human bladder cancer. Oncol. Rep. 14, 909-913.
88. Percy M.J., Mooney S.M., McMullin M.F., Flores A., Lappin T.R. and Lee F.S. (2003). A common polymorphism in the oxygen-dependent degradation (ODD) domain of hypoxia inducible factor-1alpha (HIF-1alpha) does not impair Pro-564 hydroxylation. Mol. Cancer 2, 31.
89. Quintero M., Mackenzie N. and Brennan P.A. (2004). Hypoxia-inducible factor 1 (HIF-1) in cancer. Eur. J. Surg. Oncol. 30, 465-468.
90. Rapisarda A., Shoemaker R.H. and Melillo G. (2004a). Targeting topoisomerase I to inhibit hypoxia inducible factor 1. Cell Cycle 3, 172-175.
91. Rapisarda A., Uranchimeg B., Sordet O., Pommier Y., Shoemaker R.H. and Melillo G. (2004b). Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res. 64, 1475-1482.
92. Richard D.E., Berra E. and Pouyssegur J. (2000). Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1alpha in vascular smooth muscle cells. J. Biol. Chem. 275, 26765-26771.
93. Ricker J.L., Chen Z., Yang X.P., Pribluda V.S., Swartz G.M. and Van Waes C. (2004). 2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma. Clin. Cancer Res. 10, 8665-8673.
94. Ryan H.E., Lo J. and Johnson R.S. (1998). HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J. 17. 3005-3015.
95. Ryan H.E., Poloni M., McNulty W., Elson D., Gassmann M., Arbeit J.M and Johnson R.S. (2000). Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res. 60, 4010-4015.
96. Salceda S., Beck I., Srinivas V. and Caro J. (1997). Complex role of protein phosphorylation in gene activation by hypoxia. Kidney Int. 51, 556-559.
97. Schindl M., Schoppmann S.F., Samonigg H., Hausmaninger H., Kwasny W., Gnant M., Jakesz R., Kubista E., Birner P. and Oberhuber G. (2002). Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin. Cancer Res. 8, 1831-1837.
98. Schoppmann S.F., Fenzl A., Schindl M., Bachleitner-Hofmann T., Nagy K., Gnant M., Horvat R., Jakesz R. and Birner P. (2006). Hypoxia inducible factor-1alpha correlates with VEGF-C expression and lymphangiogenesis in breast cancer. Breast Cancer Res. Treat.
99. Semenza G.L. (2003). Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3, 721-732.
100. Semenza G.L., Artemov D., Bedi A., Bhujwalla Z., Chiles K., Feldser D., Laughner E., Ravi R., Simons J., Taghavi P. and Zhong H. (2001). The metabolism of tumours': 70 years later. Novartis Found. Symp. 240, 251-260.
101. Shao Z.Q., Zheng S.B., Xiao Y.J., Tan W.L., Chen T., Qi H., Jiang Y.D., Yu Z.C. and Zhang H.J. (2005). Expressions of hypoxia inducible factor-1alpha and vascular endothelial growth factor in human renal cell carcinoma. Di Yi Jun Yi Da Xue Xue Bao 25, 1034-1036.
102. Shibaji T., Nagao M., Ikeda N., Kanehiro H., Hisanaga M., Ko S., Fukumoto A. and Nakajima Y. (2003). Prognostic significance of HIF-1 alpha overexpression in human pancreatic cancer. Anticancer Res. 23, 4721-4727.
103. Sodhi A., Montaner S., Miyazaki H. and Gutkind J.S. (2001). MAPK and Akt act cooperatively but independently on hypoxia inducible factor-1alpha in rasV12 upregulation of VEGF. Biochem. Biophys. Res. Commun. 287, 292-300.
104. Sondergaard K.L., Hilton D.A., Penney M., Ollerenshaw M. and Demaine A.G. (2002). Expression of hypoxia-inducible factor 1alpha in tumours of patients with glioblastoma. Neuropathol. Appl. Neurebiol. 28, 210-217.
105. Stiehl D.P., Jelkmann W., Wenger R.H. and Hellwig-Burgel T. (2002). Normoxic induction of the hypoxia-inducible factor 1alpha by insulin and interleukin-lbeta involves the phosphatidylinositol 3-kinase pathway. FEBS Lett. 512, 157-162.
106. Swinson D.E., Jones J.L., Cox G., Richardson D., Harris A.L. and O'Byrne K.J. (2004). Hypoxia-inducible factor-1 alpha in non small cell lung cancer: relation to growth factor, protease and apoptosis pathways. Int. J. Cancer 111, 43-50.
107. Tacchini L., Dansi P., Matteucci E. and Desiderio M.A. (2001). Hepatocyte growth factor signalling stimulates hypoxia inducible factor-1 (HIF-1) activity in HepG2 hepatoma cells. Carcinogenesis 22, 1363-1371.
108. Takahashi R., Tanaka S., Hiyama T., Ito M., Kitadai Y., Sumii M., Haruma K. and Chayama K. (2003). Hypoxia-inducible factor-1alpha expression and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncol. Rep. 10, 797-802.
109. Talks K.L., Turley H., Gatter K.C., Maxwell P.H., Pugh C.W., Ratcliffe P.J. and Harris A.L. (2000). The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol. 157, 411-421.
110. Tanimoto K., Yoshiga K., Eguchi H., Kaneyasu M., Ukon K., Kumazaki T., Oue N., Yasui W., Imai K., Nakachi K., Poellinger L. and Nishiyama M. (2003). Hypoxia-inducible factor-1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance. Carcinogenesis 24, 1779-1783.
111. Theodoropoulos V.E., Lazaris A., Sofras F., Gerzelis I., Tsoukala V., Ghikonti I., Manikas K. and Kastriotis I. (2004). Hypoxia-inducible factor 1 alpha expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. Eur. Urol. 46, 200-208.
112. Theodoropoulos V.E., Lazaris A.C., Kastriotis I., Spiliadi C., Theodoropoulos G.E., Tsoukala V., Patsouris E. and Sofras F. (2005). Evaluation of hypoxia-inducible factor 1 alpha overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma. BJU Int. 95, 425-431.
113. Tian H., McKnight S.L. and Russell D.W. (1997). Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev. 11, 72-82.
114. Urano N., Fujiwara Y., Doki Y., Tsujie M., Yamamoto H., Miyata H., Takiguchi S., Yasuda T., Yano M. and Monden M. (2006). Overexpression of hypoxia-inducible factor-1 alpha in gastric adenocarcinoma. Gastric Cancer 9, 44-49.
115. Vaupel P. (2004). Tumor microenvironmental physiology and its implications for radiation oncology. Semin. Radiat. Oncol. 14, 198-206.
116. Vleugel M.M., Greijer A.E., Shvarts A., van der Greep P., van Berkel M., Aarbodem Y., van Tinteren H., Harris A.L., van Diest P.J. and van der Wall E. (2005). Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer. J. Clin. Pathol. 58, 172-177.
117. Volm M. and Koomagi R. (2000). Hypoxia-inducible factor (HIF-1) and its relationship to apoptosis and proliferation in lung cancer. Anticancer Res. 20, 1527-1533.
118. Wang G.L. and Semenza G.L. (1995). Purification and characterization of hypoxia-inducible factor 1. J. Biol. Chem. 270, 1230-1237.
119. Wang G.L., Jiang B.H., Rue E.A. and Semenza G.L. (1995). Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. USA 92, 5510-5514.
120. Wang L., Chen Z.J., Wang Q.T., Cao W.F., Jian Y., Wang S.X. and Zhang B.H. (2006). Expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in prostate cancer and its significance. Zhonghua Nan Ke Xue 12, 57-59.
121. Warburg O. (1965). The oxygen-transferring ferment of respiration: Nobel lecture, December 10. In from Nobel lectures, physiology or medicine. Elsevier Publishing Company. Amsterdam. pp 1922-1941.
122. Wiesener M.S., Munchenhagen P.M., Berger I., Morgan N.V., Roigas J., Schwiertz A., Jurgensen J.S., Gruber G., Maxwell P.H., Loning S.A., Frei U., Maher E.R., Grone H.J. and Eckardt K.U. (2001).
123. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res. 61, 5215-5222.
124. Winter S.C., Shah K.A., Han C., Campo L., Turley H., Leek R., Corbridge R.J., Cox G.J. and Harris A.L. (2006). The relation between hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression with anemia and outcome in surgically treated head and neck cancer. Cancer.
125. Wong C., Wellman T.L. and Lounsbury K.M. (2003). VEGF and HIF-1alpha expression are increased in advanced stages of epithelial ovarian cancer. Gynecol. Oncol. 91, 513-517.
126. Wykoff C.C., Beasley N.J., Watson P.H., Turner K.J., Pastorek J., Sibtain A., Wilson G.D., Turley H., Talks K.L., Maxwell P.H., Pugh C.W., Ratcliffe P.J. and Harris A.L. (2000). Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 60, 7075-7083.
127. Xia G., Kageyama Y., Hayashi T., Hyochi N., Kawakami S. and Kihara K. (2002). Positive expression of HIF-2alpha/EPAS1 in invasive bladder cancer. Urology 59, 774-778.
128. Yoshimura H., Dhar D.K., Kohno H., Kubota H., Fujii T., Ueda S., Kinugasa S., Tachibana M. and Nagasue N. (2004). Prognostic impact of hypoxia-inducible factors 1alpha and 2alpha in colorectal cancer patients: correlation with tumor angiogenesis and cyclooxygenase-2 expression. Clin. Cancer Res. 10, 8554-8560.
129. Zhang H., Zhang Z., Xu Y., Xing L., Liu J., Li J. and Tan Q. (2004a). The expression of hypoxia inducible factor 1-alpha in lung cancer and its correlation with P53 and VEGF. J. Huazhong Univ. Sci. Technolog. Med. Sci. 24, 124-127.
130. Zhang Q., Zhang Z.F., Rao J.Y., Sato J.D., Brown J., Messadi D.V. and Le A.D. (2004b). Treatrnent with siRNA and antisense oligonucleotides targeted to HIF-1alpha induced apoptosis in human tongue squamous cell carcinornas. Int. J. Cancer 111, 849-857.
131. Zhang N., Gong K., Yang X.Y., Xin D.Q. and Na Y.Q. (2006). Expression of hypoxia-inducible factor-l-alpha, hypoxia-inducible factor-2alpha and vascular endothelial growth factor in sporadic clear cell renal cell renal cell carcinoma and their significance in the pathogenesis thereof. Zhonghua Yi Xue Za Zhi 86, 1526-1529.
132. Zhong H., De Marzo A.M., Laughner E., Lim M., Hilton D.A., Zagzag D., Buechler P., Isaacs W.B., Semenza G.L. and Simons J.W. (1999). Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 59, 5830-5835.
133. Zhong H., Semenza G.L., Simons J.W. and De Marzo A.M. (2004). Upregulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. Cancer Detect. Prev. 28, 88-93.
134. Zundel W., Schindler C., Haas-Kogan D., Koong A., Kaper F., Chen E., Gottschalk A.R., Ryan H.E., Johnson R.S., Jefferson A.B., Stokoe D. and Giaccia A.J. (2000). Loss of PTEN facilitates HIF-l-mediated gene expression. Genes Der. 14, 391-396.